scholarly journals Vancomycin-Associated Leukocytoclastic Vasculitis

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Makhawadee Pongruangporn ◽  
David J. Ritchie ◽  
Dongsi Lu ◽  
Jonas Marschall
Keyword(s):  
Staphylococcus Aureus ◽  
Skin Biopsy ◽  
Drug Administration ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Leukocytoclastic Vasculitis ◽  
Food And Drug Administration ◽  
Lower Extremities ◽  
Methicillin Resistant ◽  
Palpable Purpura ◽  
Serious Infections

Vancomycin is U.S. Food and Drug Administration (FDA) approved for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or in individuals who have failed, cannot tolerate, or are allergic to other antibiotics. Very few cases of vancomycin-associated leukocytoclastic vasculitis have been published. We report on a patient who developed pruritus and palpable purpura in both lower extremities after receiving six days of intravenous vancomycin. Skin biopsy revealed leukocytoclastic vasculitis.

scholarly journals Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus

2020 ◽  
Vol 34 ◽  
pp. 205873842092571
Author(s):  
Chanmei Lv ◽  
Jiantao Lv ◽  
Yue Liu ◽  
Qifeng Liu ◽  
Dongna Zou
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
First Line ◽  
Methicillin Resistant ◽  
First Report ◽  
First Line Therapy ◽  
Acute Hematogenous Osteomyelitis ◽  
Serious Infections ◽  
Daily Dose ◽  
Red Man Syndrome

The infection of the bone marrow system caused by methicillin-resistant Staphylococcus aureus (MRSA) leads to a variety of common diseases which usually occur in children under the age of 12. Vancomycin (VCM) is the first-line therapy for MRSA-caused serious infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin and soft-tissue infection (e.g. necrotizing fasciitis) with a recommended dosage of 15–20 μg/mL. In this study, we first report a case of a child with MRSA-caused osteomyelitis who was successfully cured by VCM at a concentration of 4.86 μg/mL. VCM’s clinical daily dose of more than 4 g was of concern in light of recent evidence suggesting the increased risks of nephrotoxicity and red man syndrome when Cmin ⩾15 μg/mL and doses ⩾10 mg/kg in children. As far as we know, this is the first report on the lower dose of VCM in children with MRSA osteomyelitis.

scholarly journals In VitroActivity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

2015 ◽  
Vol 59 (8) ◽  
pp. 5007-5009 ◽  
Author(s):  
Sandra P. McCurdy ◽  
Ronald N. Jones ◽  
Rodrigo E. Mendes ◽  
Sailaja Puttagunta ◽  
Michael W. Dunne
Keyword(s):  
Staphylococcus Aureus ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Multidrug Resistant ◽  
Surveillance Program ◽  
Drug Resistant ◽  
Methicillin Resistant ◽  
Content Type

ABSTRACTIn over a decade (2002 to 2012) ofStaphylococcus aureussurveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistantS. aureusisolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC50/90, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint. Overall, only 0.35% of the monitoredS. aureusisolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).

Treatment of Infection and Colonization Caused by Methicillin-Resistant Staphylococcus aureus

1991 ◽  
Vol 12 (01) ◽  
pp. 29-35 ◽  
Author(s):  
Henry F. Chambers
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Methicillin Resistance ◽  
Active Agent ◽  
Methicillin Resistant ◽  
Drug Of Choice ◽  
Serious Infections ◽  
Combination Regimens ◽  
Higher Doses

AbstractThe mechanism of methicillin resistance confers resistance to all available B-lactam antibiotics; consequently, B-lactam antibiotics have no role in therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections. Vancomycin remains the drug of choice. Teicoplanin and daptomycin are two investigational antibiotics related to vancomycin in structure and in spectrum of activity. In clinical trials employing relatively low doses, neither was as effective as vancomycin. Trials at higher doses are on-going. Quinolones, ciprofloxacin in particular, have been used successfully to treat infections caused by MRSA; however, the usefulness of quinolones may be limited by the tendency of resistance to emerge during therapy. Quinolones probably should be used only in combination with another active agent, such as rifampin, when treating serious infections caused by MRSA. Other agents may be active in vitro against MRSA, but clinical data showing their effectiveness are lacking. Rifampin combination regimens appear most effectively to eradicate colonization with MRSA.

Diminished Susceptibility to Daptomycin Accompanied by Clinical Failure in a Patient With Methicillin-Resistant Staphylococcus aureus Bacteremia

2006 ◽  
Vol 27 (3) ◽  
pp. 315-317 ◽  
Author(s):  
David Hirschwerk ◽  
Christine C. Ginocchio ◽  
Maureen Bythrow ◽  
Susan Condon
Keyword(s):  
Staphylococcus Aureus ◽  
Minimum Inhibitory Concentration ◽  
Dna Fingerprinting ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Inhibitory Concentration ◽  
Clinical Failure ◽  
Methicillin Resistant ◽  
Staphylococcus Aureus Bacteremia ◽  
New Information ◽  
Serious Infections

We cared for a patient with methicillin-resistant Staphylococcus aureus bacteremia who experienced clinical failure with daptomycin. The failure was accompanied by progressive elevation of the daptomycin minimum inhibitory concentration during treatment. DNA fingerprinting confirmed that the minimum inhibitory concentration elevation occurred within the same strain of methicillin-resistant Staphylococcus aureus. This observation provides important new information to clinicians who adopt this promising drug for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus.

scholarly journals Methicillin resistant Staphylococcus aureus - importance of appropriate empirical therapy in serious infections

2021 ◽  
Vol 9 (1) ◽  
pp. 56
Author(s):  
Pavan Kumar Nanchary Reddy ◽  
Anand Sutar ◽  
Sambit Sahu ◽  
Bini Thampi ◽  
Neha Keswani ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Empirical Therapy ◽  
World Health ◽  
Multi Drug Resistance ◽  
Methicillin Resistant ◽  
Healthcare Settings ◽  
Global Priority ◽  
Serious Infections ◽  
The World

India has been titled the capital of antimicrobial resistance in the world with the centre for disease dynamics, economics and policy (CDDEP) predicting two million deaths in India by 2050. As per the World Health Organisation’s global priority pathogen list of 2017, methicillin resistant Staphylococcus aureus (MRSA) has been classified as a ‘high priority’ pathogen due to its association with increased mortality rate, rising prevalence of resistance and increased burden on healthcare settings. A recent report by Indian Council of Medical Research signifies the exponential rise in the prevalence of MRSA in India, from 29% in 2009 to 39% in 2018. Serious MRSA infections are commonly associated with poor clinical outcomes coupled with increased hospitalisation stay and cost. Therefore, early identification and appropriate empiric treatment of MRSA plays a crucial role in healthcare settings. However, the constant rise in multi-drug resistance to the currently available anti-MRSA agents as well as their compromised safety profile limits its clinical use to manage severe MRSA infections. This review article explores the implications of severe MRSA infections and inappropriate empirical therapy on the clinical as well as economic outcomes. In addition, it also highlights limitations of the currently available anti-MRSA agents and the need for newer agents to manage multi drug resistant (MDR) gram positive infections.

scholarly journals Successful Daptomycin Use in a Pediatric Patient With Acute, Bilateral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus aureus

2015 ◽  
Vol 20 (5) ◽  
pp. 397-402
Author(s):  
Kelsey L. Billups ◽  
Jeremy S. Stultz
Keyword(s):  
Staphylococcus Aureus ◽  
Case Report ◽  
Pediatric Patient ◽  
Drug Administration ◽  
Inflammatory Markers ◽  
Pediatric Patients ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Safety And Efficacy ◽  
Methicillin Resistant ◽  
Minimal Data

Staphylococcus aureus is the most common bacteria associated with the development of osteomyelitis in pediatric patients. Osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA) can be difficult to safely and effectively treat. Vancomycin, linezolid, and clindamycin are commonly used to treat osteomyelitis caused by MRSA. While adult studies suggest intravenous (IV) daptomycin may by beneficial for the treatment of MRSA osteomyelitis, it is not Food and Drug Administration approved for use in pediatrics, and minimal data are available related to its use in this population. This case report describes the successful use of daptomycin (8 mg/kg/dose IV daily) combined with rifampin for 5 weeks, followed by 5 weeks of oral sulfamethoxazole/trimethoprim, for treatment of acute bilateral osteomyelitis caused by MRSA in an 8-year-old male. The patient did not initially respond to the combination of vancomycin plus rifampin and gentamicin, nor did he respond to ceftaroline treatment. After initiation of daptomycin, his fevers quickly subsided, his pain rapidly improved, and his inflammatory markers significantly decreased. While daptomycin was effective in this patient, additional research is needed to determine the true safety and efficacy of this drug for treatment of osteomyelitis caused by MRSA in pediatric patients.

Sign in / Sign up

Export Citation Format

Share Document